"An experimental oral lymphocyte trafficking agent, ozanimod (Receptos), showed modest activity against ulcerative colitis (UC) in a small, early-stage clinical trial.
In the double-blind, placebo-controlled phase 2 trial in adults wit"...
GIAZO is indicated for the treatment of mildly to moderately active ulcerative colitis in male patients 18 years of age and older.
Limitations of Use
- Effectiveness of GIAZO in the treatment of female patients was not demonstrated in clinical trials (see Clinical Trials].
- Safety and effectiveness of GIAZO therapy beyond 8 weeks have not been established.
DOSAGE AND ADMINISTRATION
The dose is three 1.1 g GIAZO tablets to be taken 2 times a day with or without food (6.6 g per day) for up to 8 weeks.
Dosage Forms And Strengths
GIAZO is available as yellow, oval, film-coated tablets containing 1.1 g balsalazide disodium, with BZT debossed on one side of the tablet.
Storage And Handling
GIAZO is available as oval, yellow, film-coated tablets containing 1.1 g balsalazide disodium, with BZT debossed on one side of the tablet.
NDC 65649-102-02 Bottles of 180 tablets
Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° and 30°C (59° and 86°F). See USP Controlled Room Temperature.
Manufactured by: Nexgen Pharma, Inc. Manufactured for: Salix Pharmaceuticals, Inc. Raleigh, NC 27615. Revised: June 2012This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 2/13/2014
Additional Giazo Information
- Giazo Drug Interactions Center: balsalazide oral
- Giazo Side Effects Center
- Giazo FDA Approved Prescribing Information including Dosage
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.